

Dear Ms. Koualsky,

Please accept my sincere apologies for the delayed response to your letters on February 27, March 10 and 17, 2023. Thank you for writing to the ministry regarding the funding of caplacizumab and for your advocacy on behalf of patients with aTTP.

We take very seriously the struggles that aTTP patients and their families have with the debilitating effects of this disease. The ministry recognizes that access to new drug therapies is important, especially in rare diseases with significant health impacts and where there are limited treatment options.

As you are likely aware, Ontario has an established process for reviewing requests for drug product funding. In order for any drug product to be funded under Ontario's public drug programs, a thorough assessment of the clinical effectiveness, safety, cost-effectiveness, and patient evidence for the drug is conducted. For approved new drugs like caplacizumab, the Canadian Agency for Drugs and Technologies in Health (CADTH) reimbursement review recommendations are instrumental in informing funding decisions. The established drug review and pan-Canadian negotiations processes support Ontario's commitment to improving access to new drug therapies while maintaining value and sustainability of our public drug programs for the present and the future.

The current review of caplacizumab by CADTH has not concluded. Details are available at: [caplacizumab | CADTH](#). The ministry looks forward to receiving the final CADTH recommendation before working with our federal, provincial and territorial partners to determine next steps.

We understand that this may not be the response that you were hoping to receive; however, we hope this information is helpful.

Thank you again for writing.

Best regards,

Patrick

Patrick Dicerni (he/him)

Assistant Deputy Minister | Health Programs and Delivery Division

Ministry of Health

647-588-5345

Ontario 